NL-OMON28041尚未招募不适用
Therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease TUMMY trial
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- one
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •age =18 years, maintenance therapy of vedolizumab (>14 weeks), diagnosed with Crohn's disease (DBC 601) or colitis ulcerosa (DBC602)
排除标准
- •age <18 years, induction therapy with vedolizumab (<14 weeks), disabled persons.
研究者
相似试验
已完成
不适用
Therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel diseaseNL-OMON55193Maxima Medisch Centrum160
招募中
不适用
Monitoring of Vedolizumab Infusion Therapy response with fecal calprotectin, ultrasound and trough serum level in Ulcerative colitis. A multicentric, prospective non-interventional StudyK51Ulcerative colitisDRKS00014249Internistische Gemeinschaftspraxis50
已完成
不适用
Prospective evaluation of vedolizumab-effects in patients with inflammatory bowel diseasesulcerative colitis and Crohn's diseaseJPRN-UMIN000039916Saitama Medical Center, Saitama Medical University50
招募中
不适用
Prospective evaluation of vedolizumab-effects and safety in patients with inflammatory bowel diseases (VED IBD Cohort Study)JPRN-UMIN000040175Saitama Medical Center, Saitama Medical University50
暂停
不适用
Pharmacokinetics and efficacy of Vedolizumab in inflammatory bowel diseasesulcerative colitis and Crohn's diseaseJPRN-UMIN000045425Shiga University of Medical Science50